8 million pregnant women, the use of ondansetron in first trimester was associated with an increased risk of cleft lip, jaw and palate 3 additional cases per 10, 000 women treated; adjusted relative risk, 1
:: تقديرا لمجهود صاحب الموضوع الروابط وسيرفرات المشاهدة والتحميل متاحة فقط لأعضاء منتدى الدي في دي - سجل الدخول أو للتسجيل اضغط هنا ::
:: Only registered members can view links - Log in or to register click here ::
While two phase II trials by Genentech targeting the complement protein called factor D in geographic atrophy patients were not successful, a phase II trial by Apellis targeting a different complement protein called C3 showed promising results